Tevis Investment Management Increases Stock Holdings in Medtronic PLC $MDT

Tevis Investment Management grew its stake in Medtronic PLC (NYSE:MDT) by 15.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 62,241 shares of the medical technology company’s stock after acquiring an additional 8,167 shares during the quarter. Medtronic comprises about 2.7% of Tevis Investment Management’s portfolio, making the stock its 10th biggest position. Tevis Investment Management’s holdings in Medtronic were worth $4,914,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Monetary Solutions Ltd bought a new stake in Medtronic during the fourth quarter valued at about $27,000. Anfield Capital Management LLC raised its holdings in Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 230 shares in the last quarter. Acumen Wealth Advisors LLC bought a new position in Medtronic in the fourth quarter worth about $29,000. Imprint Wealth LLC purchased a new stake in shares of Medtronic during the third quarter valued at about $31,000. Finally, Basepoint Wealth LLC purchased a new stake in shares of Medtronic during the fourth quarter valued at about $32,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Price Performance

Shares of NYSE MDT opened at $94.13 on Thursday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. The company has a market cap of $120.49 billion, a PE ratio of 25.24, a P/E/G ratio of 2.47 and a beta of 0.55. The business has a 50-day simple moving average of $83.88 and a two-hundred day simple moving average of $86.08. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The business had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. During the same quarter in the previous year, the firm earned $1.62 earnings per share. The company’s revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. As a group, equities analysts expect that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, July 17th. Shareholders of record on Friday, June 26th were given a dividend of $0.72 per share. The ex-dividend date of this dividend was Friday, June 26th. This represents a $2.88 annualized dividend and a yield of 3.1%. This is a boost from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s payout ratio is presently 77.21%.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Bank of America issued a bullish outlook ahead of earnings. The firm sees continued momentum from one of Medtronic’s key growth businesses and believes an additional catalyst could develop, potentially improving investor expectations before the results. Bank of America makes bullish call on 77-year-old healthcare stock
• Positive Sentiment: Medtronic is one dividend increase away from Dividend King status. The company has raised its dividend for 49 consecutive years and currently pays $0.72 per quarter, or $2.88 annually. Reaching the 50-year milestone could reinforce MDT’s appeal to income-focused and defensive investors. Medtronic plc is Closing in on Dividend King Status
• Neutral Sentiment: BTIG reaffirmed its “Buy” rating but set a $91 price target, below MDT’s recent trading level. The recommendation supports the long-term outlook, while the target suggests limited near-term upside at current levels. Other recent analyst targets have been mixed, with a reported median of $101. BTIG reaffirms buy rating on Medtronic
• Neutral Sentiment: Value-investor comparisons with Agilent Technologies and proxy-recommendation coverage may attract attention, but neither provides a clear new earnings or fundamental catalyst for MDT. MDT vs. A: Which Stock Should Value Investors Buy Now?
• Negative Sentiment: Medtronic faces a potential injunction in its Applied Medical case. An adverse ruling could create operational or legal uncertainty and represents a risk ahead of earnings. Medtronic faces potential injunction in Applied Medical case
• Negative Sentiment: Reported insider activity showed eight sales and no purchases over the past six months, while estimated CEO compensation increased year over year. These signals could weigh modestly on sentiment, although they do not necessarily indicate a change in Medtronic’s fundamentals. Medtronic CEO 2026 Pay Revealed

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the transaction, the executive vice president owned 37,227 shares in the company, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.26% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on MDT shares. Evercore set a $105.00 price target on shares of Medtronic in a report on Monday, July 6th. TD Cowen reduced their price objective on shares of Medtronic from $119.00 to $100.00 and set a “buy” rating for the company in a research note on Friday, July 10th. Truist Financial decreased their target price on shares of Medtronic from $95.00 to $86.00 and set a “hold” rating for the company in a research report on Thursday, June 4th. Sanford C. Bernstein lowered their target price on shares of Medtronic from $112.00 to $97.00 and set an “outperform” rating for the company in a research note on Thursday, June 4th. Finally, JPMorgan Chase & Co. cut their price target on shares of Medtronic from $100.00 to $86.00 and set a “neutral” rating on the stock in a report on Thursday, June 4th. Eighteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $98.83.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).